Some of the best links we picked up around the internet
The latest clinical update includes dosing announcements for two trials, with the first patients now treated with Epicrispr Biotechnologies’ EPI-321...
The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...